Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fimasartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 10/20 | 0.75 |
| ▸ | PPARG | P37231 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fimasartan SCHEMBL29376979 | 1.00 | AGTR1 (0.75) | AGTR1PPARG | |
| Fimasartan SCHEMBL28095948 | 0.99 | AGTR1 (0.74) | AGTR1PPARG | |
| SCHEMBL6964867 | 0.94 | AGTR1 (0.75) | AGTR1PPARG | |
| SCHEMBL6963516 | 0.94 | AGTR1 (0.67) | AGTR1 | |
| SCHEMBL7820489 | 0.92 | AGTR1 (0.64) | AGTR1PPARG | |
| SCHEMBL17434766 | 0.92 | AGTR1 (0.66) | AGTR1PPARG | |
| SCHEMBL6964925 | 0.91 | AGTR1 (0.63) | AGTR1PPARG | |
| SCHEMBL9843837 | 0.90 | AGTR1 (0.59) | AGTR1PPARG | |
| SCHEMBL7819440 | 0.90 | PPARG (0.61) | AGTR1PPARG | |
| SCHEMBL6971961 | 0.89 | PPARG (0.61) | AGTR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0991627-B1 | PYRIMIDINONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS AND THE PROCESS FOR PREPARING THE SAME | BORYUNG PHARM (KR) | 2003-07-02 | — | — | EP | claimed |
| CN-107973784-B | Synthesis method of fimasartan | 珠海市海瑞德生物科技有限公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-109485640-B | Preparation method of fimasartan impurity | 合肥创新医药技术有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-106674206-B | Co-crystal medicine for treating heart failure | 顾国明 | 2021-01-19 | — | — | CN | disclosed |
| WO-2020141825-A1 | TABLET AND METHOD OF PREPARING SAME | 보령제약 주식회사 | 2020-07-09 | — | — | WO | disclosed |
| US-20200206196-A1 | Antiviral Drugs | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2020-07-02 | — | — | US | disclosed |
| US-20180311241-A1 | PHARMACEUTICAL SYNERGISTIC COMBINATION | CADILA HEALTHCARE LIMITED (IN) | 2018-11-01 | — | — | US | disclosed |
| EP-2868316-B1 | PHARMACEUTICAL COMPOSITION CONTAINING FIMASARTAN AND HYDROCHLOROTHIAZIDE | BORYUNG PHARM (KR) | 2017-12-06 | — | — | EP | disclosed |
| WO-2017072636-A1 | PHARMACEUTICAL SYNERGISTIC COMBINATION | CADILA HEALTHCARE LIMITED (IN) | 2017-05-04 | — | — | WO | disclosed |
| US-9592233-B2 | Pharmaceutical combination drug | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2017-03-14 | — | — | US | disclosed |
| US-20120264772-A1 | ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITION | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2012-10-18 | — | — | US | disclosed |
| WO-2011090323-A2 | NOVEL PREPARATION METHOD OF 2-(2-N-BUTYL-4-HYDROXY-6-METHYL-PYRIMIDIN-5-YL)-N,N-DIMETHYLACETAMIDE | BORYUNG PHARMACEUTICAL CO., LTD (KR) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011090323-A2 | NOVEL PREPARATION METHOD OF 2-(2-N-BUTYL-4-HYDROXY-6-METHYL-PYRIMIDIN-5-YL)-N,N-DIMETHYLACETAMIDE | BORYUNG PHARMACEUTICAL CO., LTD (KR) | 2011-07-28 | — | — | WO | disclosed |
| EP-1436283-B1 | METHOD FOR PREPARING PYRIMIDINONE COMPOUND AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | BORYUNG PHARM (KR) | 2008-01-23 | — | — | EP | disclosed |
| US-7309788-B2 | Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2007-12-18 | — | — | US | disclosed |
| US-20040266800-A1 | Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2004-12-30 | — | — | US | disclosed |
| EP-0991627-B1 | PYRIMIDINONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS AND THE PROCESS FOR PREPARING THE SAME | BORYUNG PHARM (KR) | 2003-07-02 | — | — | EP | disclosed |
| US-6294542-B1 | Pyrimidinone compounds, pharmaceutical compositions containing the compounds and the process for preparing the same | BORYUNG PHARMACEUTICAL CO. LTD. (KR) | 2001-09-25 | — | — | US | disclosed |
| EP-0991627-A1 | PYRIMIDINONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS AND THE PROCESS FOR PREPARING THE SAME | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999055681-A1 | PYRIMIDINONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS AND THE PROCESS FOR PREPARING THE SAME | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266800-A1 | Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof | AGTR2, AGTR1, ACE | AGTR1 2/4885PPARG 345/4885 |
| US-20120264772-A1 | ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITION | AGTR2, AGTR1, AGT | AGTR1 2/4885PPARG 1178/4885 |
| US-20200206196-A1 | Antiviral Drugs | ACE2, MAVS, EIF2AK2 | AGTR1 19/4885PPARG 3576/4885 |
| US-20180311241-A1 | PHARMACEUTICAL SYNERGISTIC COMBINATION | MME, REN, PCSK9 | AGTR1 8/4885PPARG 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.